The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ELEVEN BIOTHERAPEUTICS, INC. | COM | 286221106 | 3,922 | 4,841,591 | SH | DFND | 1,2,3 | 4,841,591 | 0 | 0 | |
ZAFGEN, INC. | COM | 98885E103 | 972 | 210,371 | SH | DFND | 1,2,3 | 210,371 | 0 | 0 | |
CYTOMX THERAPEUTICS, INC. | COM | 23284F105 | 70,093 | 3,320,348 | SH | DFND | 1,2,3 | 3,320,348 | 0 | 0 | |
KALA PHARMACEUTICALS INC. | COM | 483119103 | 30,590 | 1,654,425 | SH | DFND | 1,2,3 | 1,654,425 | 0 | 0 | |
RHYTHM PHARMACEUTICALS, INC. | COM | 76243J105 | 115,701 | 3,981,437 | SH | DFND | 1,2,3 | 3,981,437 | 0 | 0 |